Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic features, melanoma-specific survival, and recurrenc...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-11-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748211053567 |
| _version_ | 1818567436782272512 |
|---|---|
| author | Avani M. Kolla BPhil Gerardo A. Vitiello MD Erica B. Friedman MD James Sun MD Aishwarya Potdar MS Hala Daou BS Norma E. Farrow MD Clara R. Farley MD John T. Vetto MD Dale Han MD Marvi Tariq MD Georgia M Beasley MD Carlo M. Contreras MD Michael Lowe MD Jonathan S. Zager MD Iman Osman MD Russell S. Berman MD Tracey N. Liebman MD Jennifer A. Stein MD PhD Ann Y. Lee MD |
| author_facet | Avani M. Kolla BPhil Gerardo A. Vitiello MD Erica B. Friedman MD James Sun MD Aishwarya Potdar MS Hala Daou BS Norma E. Farrow MD Clara R. Farley MD John T. Vetto MD Dale Han MD Marvi Tariq MD Georgia M Beasley MD Carlo M. Contreras MD Michael Lowe MD Jonathan S. Zager MD Iman Osman MD Russell S. Berman MD Tracey N. Liebman MD Jennifer A. Stein MD PhD Ann Y. Lee MD |
| author_sort | Avani M. Kolla BPhil |
| collection | DOAJ |
| description | Background Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic features, melanoma-specific survival, and recurrence-free survival by substage in a large, multi-institutional cohort of primary acral lentiginous melanoma patients. Methods Retrospective review of the United States Melanoma Consortium database, a multi-center prospectively collected database of acral lentiginous melanoma patients treated between January 2000 and December 2017. Results Of the 433 primary acral lentiginous melanoma patients identified (median [range] age: 66 [8–97] years; 53% female, 83% white), 66% presented with stage 0–2 disease and the median time of follow-up for the 392 patients included in the survival analysis was 32.5 months (range: 0–259). The 5-year melanoma-specific survivals by stage were 0 = 100%, I = 93.8%, II = 76.2%, III = 63.4%, IIIA = 80.8%, and IV = 0%. Thicker Breslow depth ((HR) = 1.13; 95% CI = 1.05–1.21; P < .001)) and positive nodal status ((HR) = 1.79; 95% CI = 1.00–3.22; P = .050)) were independent prognostic factors for melanoma-specific survival. Breslow depth ((HR = 1.13; 95% CI = 1.07–1.20; P < .001), and positive nodal status (HR = 2.12; 95% CI = 1.38–3.80; P = .001) were also prognostic factors for recurrence-free survival. Conclusion In this cohort of patients, acral lentiginous melanoma was associated with poor outcomes even in early stage disease, consistent with prior reports. Stage IIB and IIC disease were associated with particularly low melanoma-specific and recurrence-free survival. This suggests that studies investigating adjuvant therapies in stage II patients may be especially valuable in acral lentiginous melanoma patients. |
| first_indexed | 2024-12-14T06:23:23Z |
| format | Article |
| id | doaj.art-57f410acb38d4768a497f22089e561a6 |
| institution | Directory Open Access Journal |
| issn | 1073-2748 |
| language | English |
| last_indexed | 2024-12-14T06:23:23Z |
| publishDate | 2021-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj.art-57f410acb38d4768a497f22089e561a62022-12-21T23:13:45ZengSAGE PublishingCancer Control1073-27482021-11-012810.1177/10732748211053567Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival AnalysisAvani M. Kolla BPhilGerardo A. Vitiello MDErica B. Friedman MDJames Sun MDAishwarya Potdar MSHala Daou BSNorma E. Farrow MDClara R. Farley MDJohn T. Vetto MDDale Han MDMarvi Tariq MDGeorgia M Beasley MDCarlo M. Contreras MDMichael Lowe MDJonathan S. Zager MDIman Osman MDRussell S. Berman MDTracey N. Liebman MDJennifer A. Stein MD PhDAnn Y. Lee MDBackground Acral lentiginous melanoma is associated with worse survival than other subtypes of melanoma. Understanding prognostic factors for survival and recurrence can help better inform follow-up care. Objectives To analyze the clinicopathologic features, melanoma-specific survival, and recurrence-free survival by substage in a large, multi-institutional cohort of primary acral lentiginous melanoma patients. Methods Retrospective review of the United States Melanoma Consortium database, a multi-center prospectively collected database of acral lentiginous melanoma patients treated between January 2000 and December 2017. Results Of the 433 primary acral lentiginous melanoma patients identified (median [range] age: 66 [8–97] years; 53% female, 83% white), 66% presented with stage 0–2 disease and the median time of follow-up for the 392 patients included in the survival analysis was 32.5 months (range: 0–259). The 5-year melanoma-specific survivals by stage were 0 = 100%, I = 93.8%, II = 76.2%, III = 63.4%, IIIA = 80.8%, and IV = 0%. Thicker Breslow depth ((HR) = 1.13; 95% CI = 1.05–1.21; P < .001)) and positive nodal status ((HR) = 1.79; 95% CI = 1.00–3.22; P = .050)) were independent prognostic factors for melanoma-specific survival. Breslow depth ((HR = 1.13; 95% CI = 1.07–1.20; P < .001), and positive nodal status (HR = 2.12; 95% CI = 1.38–3.80; P = .001) were also prognostic factors for recurrence-free survival. Conclusion In this cohort of patients, acral lentiginous melanoma was associated with poor outcomes even in early stage disease, consistent with prior reports. Stage IIB and IIC disease were associated with particularly low melanoma-specific and recurrence-free survival. This suggests that studies investigating adjuvant therapies in stage II patients may be especially valuable in acral lentiginous melanoma patients.https://doi.org/10.1177/10732748211053567 |
| spellingShingle | Avani M. Kolla BPhil Gerardo A. Vitiello MD Erica B. Friedman MD James Sun MD Aishwarya Potdar MS Hala Daou BS Norma E. Farrow MD Clara R. Farley MD John T. Vetto MD Dale Han MD Marvi Tariq MD Georgia M Beasley MD Carlo M. Contreras MD Michael Lowe MD Jonathan S. Zager MD Iman Osman MD Russell S. Berman MD Tracey N. Liebman MD Jennifer A. Stein MD PhD Ann Y. Lee MD Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis Cancer Control |
| title | Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis |
| title_full | Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis |
| title_fullStr | Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis |
| title_full_unstemmed | Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis |
| title_short | Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis |
| title_sort | acral lentiginous melanoma a united states multi center substage survival analysis |
| url | https://doi.org/10.1177/10732748211053567 |
| work_keys_str_mv | AT avanimkollabphil acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT gerardoavitiellomd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT ericabfriedmanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT jamessunmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT aishwaryapotdarms acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT haladaoubs acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT normaefarrowmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT clararfarleymd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT johntvettomd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT dalehanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT marvitariqmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT georgiambeasleymd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT carlomcontrerasmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT michaellowemd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT jonathanszagermd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT imanosmanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT russellsbermanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT traceynliebmanmd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT jenniferasteinmdphd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis AT annyleemd acrallentiginousmelanomaaunitedstatesmulticentersubstagesurvivalanalysis |